Bluebird on the Go with Multiple Positive Trial Data
Bluebird bio (BLUE) announced data from its different trials, including Phase 1/2 clinical trial for sickle cell disease and from a Phase 3 clinical trial for transfusion-dependent beta-thalassemia patients.
Ongoing Phase 1/2 clinical trial HGB-206 aims to assess the potential of LentiGlobin in treating adolescents and adults with sickle cell disease. As on the data cutoff date, 37 patients had been treated. Group C showed promising results as all the patients included in the cohort stopped regular blood transfusions. These patients also remained transfusion-free